The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available for many viral...
Infections with Clostridioides difficile (for short: C. difficile) are often recurrent, because dormant stages of the bacterium persist in the intestine. Thus far, there was no drug that can effectively combat the...
In the ImageTox project, the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the CISPA Helmholtz Center for Information Security are pooling their expertise in the fields of drug discovery and...
Systematically attenuating DNA targeting activity can achieve CRISPR-driven editing in bacteria, greatly boosting colony counts and even increasing the frequency of precise genome editing. This was shown in a study of...
Dr Yannic Bartsch's TWINCORE junior research group "Antiviral Antibody Omics" is being funded as a Helmholtz Young Investigator Group (HYIG). Over the next five years, the immunologist will receive a total of 1.5...
Before new drugs can be tested in animal experiments and later in clinical trials, they must undergo a large number of laboratory tests. This involves the use of so-called cell lines, i.e. human or animal cells of a...
The 2022 Prize for Translational Infection Research of the German Center for Infection Research (DZIF), endowed with 5,000 euros, goes to the DZIF scientist and epidemiologist Gérard Krause, head of the department...
The pathogen Pseudomonas aeruginosa is the cause of a large number of serious infections and places a particular burden on immunocompromised patients. The increasing spread of antimicrobial resistance makes it even more...
